Email this article 
Patients with primary myelofibrosis: treatment and quality of life
- Authors: Meshcheryakova L.M.1, Porotkova O.V.2, Kovaleva L.G.1, Kolosova L.Y.1
-
Affiliations:
- Hematological Research Center
- Regional Clinical Hospital № 1
- Issue: Vol 7, No 2 (2012)
- Pages: 6-13
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 22.05.2012
- URL: https://oncohematology.abvpress.ru/ongm/article/view/56
- DOI: https://doi.org/10.17650/1818-8346-2012-7-2-6-13
- ID: 56
Cite item
Full Text
Abstract
Primary myelofibrosis (PMF) is one of the diseases that cannot be cured using modern methods of conservative therapy. Therefore, treatment aimed at reducing PMF severity and improving patient’s quality of life. In this article, a comparative analysis of treatment response and quality of life depending on therapy using was shown. Partial remission rate at approximately the same level after α-interferon treatment (55.3 %) and after cytotoxic drug (48.8 %) was observed. Significant improvement in quality of life during α-interferon treatment was revealed.
Keywords
About the authors
L. M. Meshcheryakova
Hematological Research Center
Author for correspondence.
Russian Federation
O. V. Porotkova
Regional Clinical Hospital № 1Russian Federation
L. G. Kovaleva
Hematological Research CenterRussian Federation
L. Yu. Kolosova
Hematological Research CenterRussian Federation
References
Supplementary files
